PreMD Inc.
Medical Devices & Tech
4211 Yonge St., Ste. 615
Toronto, Ontario M2P 2A9 Canada
phone: 416-222-3449
fax: 416-222-4533
Symbol PMD
Exchange TSX
Founded 0
Employees
www.premdinc.com
Research Sector Medical Devices & Tech
Summary Description
Non-invasive tests designed to detect and monitor a range of diseases.
Management
Brent Norton, MD, MBA, President and Chief Executive Officer; Michael Evelegh, PhD, Executive Vice President, Clinical and Regulatory Affairs; Ron Hosking, CA, Vice President, Finance, and Chief Financial Officer; Tim Currie, BA, Vice President, Corporate Development
Ownership
Financials


* numbers in thousands

 
Keywords
diagnostics, colorectal, cancer, coronary, artery, disease, lung, cancer

Comment | Printable Version | Oct. 01, 2008
If you work for PreMD Inc. and want to update this profile, click here


Description
PreMD (formerly IMI International Medical Innovation) licenses and manages the development and commercialization of predictive medicine technologies designed to detect and monitor a range of diseases, including colorectal cancer, coronary artery disease, and lung cancer.
Products / Services
The company's cardiovascular risk assessment technology, PREVU Skin Sterol Test, assesses a patient's risk of heart disease by non-invasively measuring the amount of cholesterol in the skin tissues.
Technology / Differentiation
PreMD's non- or minimally-invasive tests for early-stage colorectal, lung and breast cancers detect a cancer-associated sugar in a sample of rectal mucus, sputum and breast nipple aspirate fluid, respectively. The cancer tests are in development.
Competitors / Substitutes / Alternatives
Abbott Laboratories, Beckman Coulter Inc, Roche Diagnostics Corporation
Strategy
PreMD focuses its research and development efforts on serious or life-threatening diseases such as cardiovascular disease and cancer, and is developing a test for breast cancer.


2008-10-04-536